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Background: Transient receptor potential cation channel subfamily M member 8 (TRPM8) is activated by cold
temperature in vitro and has been demonstrated to act as a ‘cold temperature sensor’ in vivo. Although it is known
that agonists of this ‘cold temperature sensor’, such as menthol and icilin, cause a transient increase in body
temperature (Tb), it is not known if TRPM8 plays a role in Tb regulation. Since TRPM8 has been considered as a
potential target for chronic pain therapeutics, we have investigated the role of TRPM8 in Tb regulation.
Results: We characterized five chemically distinct compounds (AMG0635, AMG2850, AMG8788, AMG9678, and
Compound 496) as potent and selective antagonists of TRPM8 and tested their effects on Tb in rats and mice
implanted with radiotelemetry probes. All five antagonists used in the study caused a transient decrease in Tb
(maximum decrease of 0.98°C). Since thermoregulation is a homeostatic process that maintains Tb about 37°C,
we further evaluated whether repeated administration of an antagonist attenuated the decrease in Tb. Indeed,
repeated daily administration of AMG9678 for four consecutive days showed a reduction in the magnitude of
the Tb decrease Day 2 onwards.
Conclusions: The data reported here demonstrate that TRPM8 channels play a role in Tb regulation. Further,
a reduction of magnitude in Tb decrease after repeated dosing of an antagonist suggests that TRPM8’s role in
Tb maintenance may not pose an issue for developing TRPM8 antagonists as therapeutics.
Keywords: TRPM8 antagonist, AMG0635, AMG2850, AMG8788, AMG9678, Compound 496, Body temperature
regulationBackground
Cold sensation is derived from activation of the somato-
sensory system by a cold stimulus. Studies by Hansel
and Zimmerman in the 1950s demonstrated that cold
temperatures evoke action potentials in peripheral nerves
[1,2]. Further, they have linked the effects of menthol to
cold-responsive fibers by showing that menthol shifts the
activation of cold-responsive fibers to warmer tempera-
tures [3]. Calcium imaging and patch clamp studies in
dissociated trigeminal and dorsal root ganglion neurons
have revealed that cold stimuli induce calcium influx,
suggesting direct opening of calcium-permeable ion
channels by cold [4-7]. Search for an ion channel that* Correspondence: ngavva@amgen.com
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reproduction in any medium, provided the orresponds to menthol and cold led to the cloning of
TRPM8 that is activated by cold stimuli of <28.4°C [8,9].
TRPM8 is also activated by compounds that elicit a cool-
ing sensation such as icilin (AG-3-5) [9] and its analo-
gues, as well as endogenous lysophospholipids [10] and
PIP2 [11].
A number of TRP channels are activated at distinct
ranges of temperature that span from noxious cold to
noxious heat and are believed to act as thermosensors
in vivo [12], hence named ‘thermoTRPs’ [13]. Knockout
mouse studies revealed that i) TRPV1 is required for hot
temperature sensing [14], ii) TRPV3 is required for warm
temperature sensing [15], iii) TRPV4 is required for
warm temperature discrimination [16], and iv) TRPM8 is
required for sensing innocuous ambient cold temp-
eratures [17-21]. TRPA1 is reported to be activated by
noxious cold (<10°C) in vitro [22,23], and to act as atd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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TRPM8 have been reported to play a role in cold hyper-
sensitivity [25,26]. Correlating with the cold sensing
function, TRPM8 is expressed in the sensory neurons of
the trigeminal and dorsal root ganglia and the peripheral
nerve endings in the areas of the body that could be
exposed to environmental cold temperatures (skin, oral
cavity, inner ear, and nasal mucosa) [6,8,9,27-29].
TRP channel agonists such as capsaicin [30,31], resini-
feratoxin [30], menthol [32], and icilin [33] are known
to alter Tb; however, the involvement of TRP channels
in the regulation of Tb was not known definitively until
recently (reviewed in [12,31]). We have reported that
TRPV1 is tonically active in vivo and involved in Tb
maintenance [34,35] by negative modulation of ther-
mogenesis and vasoconstriction based on the fact that
i) a variety of TRPV1 antagonists caused hyperthermia in
multiple species [34], ii) TRPV1 antagonists did not
cause hyperthermia in TRPV1 knockout mice [35], and
iii) TRPV1 antagonists increase thermogenesis and vaso-
constriction [35]. Further, clinical studies demonstrated
that TRPV1 antagonists cause a rightward shift in heat
tolerance by 2–4°C [36,37] suggesting the impairment of
heat detection confirming the ‘heat sensor’ function of
TRPV1. Menthol and icilin have been reported to cause
a transient rise in Tb [32,33,38,39], and it was also
demonstrated that the menthol and cold temperature
induced increase in Tb is TRPM8 mediated (i.e., both
menthol and cold temperature caused an increase in Tb
only in wild type but not in TRPM8 knockout mice)
[40]. However, it is not known if TRPM8 itself is tonic-
ally active or even if it is involved in homeostatic main-
tenance of Tb. Here, we report the characterization of
novel TRPM8 antagonists and their effect on Tb. Based
on the data presented here we conclude that TRPM8
channels play a role in Tb regulation.
Results
Characterization of TRPM8 antagonists
In our efforts to identify TRPM8 antagonists, we screened
compound libraries and found several chemotypes that
act as potent antagonists. Here, we describe the charac-
terization of compounds AMG0635, AMG2850, AMG8788,
AMG9678, and Compound 496. All compounds potently
inhibited the menthol and cold-induced increase in intra-
cellular calcium in cells expressing rat TRPM8 (Figure 1;
Table 1). None of the compounds activated TRPM8 at
concentrations up to 40 μM, as measured by an aequorin
luminescence assay that measures an increase in intracel-
lular calcium in cells expressing TRPM8, indicating that
they do not act as partial agonists. The rank order of the
compound potency as antagonists at rat TRPM8 activated
by menthol is: Compound 496 >AMG9678>AMG0635 >
AMG8788 >AMG2850. All compounds appeared to bemore potent at blocking cold activation of TRPM8 com-
pared to blocking menthol activation (Table 1). All com-
pounds were found to be selective for TRPM8 relative
to the recombinant TRP family members that we have
tested (allyl isothiocyanate activated TRPA1, capsaicin
activated TRPV1, 2-Aminoethoxydiphenyl borate acti-
vated TRPV3, and 4α-phorbol 12, 13-didecanoate acti-
vated TRPV4 (Table 1). The plasma half-life (T1/2) of the
antagonists in rats for AMG0635, AMG2850, AMG8788,
AMG9678, and Compound 496 is 2.8, 3.5, 6.7, 7.6, and
3.4 h, respectively.
TRPM8 blockade in vivo elicits a transient decrease in
body temperature
Since agonists of TRPM8, icilin and menthol are known
to increase Tb [32,33], we evaluated the effects of all five
TRPM8 antagonists on Tb in rats or mice implanted
with radiotelemetry probes. Different oral doses have
been chosen based on the potency and pharmacokinetic
properties of the antagonists. All antagonists lowered Tb
with an overall maximum decrease of ~0.98°C (Table 2
and Figure 2). In a 2 h Tb recording experiment,
AMG8788 at 30 mg/kg (p.o.) produced a significant de-
crease of Tb from 40 min (t10 = 2.55; p < 0.05) to 70 min
(t10 = 2.61; p < 0.05) (Figure 2A) post dosing. The max-
imum decrease in Tb was 0.53°C at 40 min and plasma
concentration was 1.5 ± 0.6 μM at 2 h post dosing. In a
4 h Tb recording experiment, AMG2850 at 100 mg/kg
(p.o.) produced a significant decrease of Tb from 40 min
(t10 = 2.26; p < 0.05) to 4 h post-dosing (t10 = 4.38;
p < 0.001) (Figure 2B). The maximum decrease in Tb was
0.98°C at 140 min (t10 = 4.38; p < 0.001) post dosing and
plasma concentration was 22 ± 0.8 μM at 4 h post
dosing. In a 2 h Tb recording experiment, AMG0635
at 3 mg/kg (p.o.) produced a significant decrease of
Tb from 40 min (t10 = 1.89; p < 0.05) to 120 min (t10 =
5.88; p < 0.0001) post-dosing. The maximum decrease
in Tb was 0.47°C at 120 min and plasma concentration
was 0.38 ± 0.04 μM at 120 min post dosing (Table 2).
In a 4 h Tb recording experiment, Compound 496 at
30 mg/kg (p.o., n = 6) produced a significant decrease of
Tb from 30 min (t10 = 2.46; p < 0.05) to 180 min
(t10 = 2.64; p < 0.05) post dosing. The maximum decrease
in Tb was 0.64°C at 100 min (t10 = 3.24; p < 0.01) and
plasma concentration was 14.9 ± 0.95 μM at 100 min
post dosing (Table 2).
Further, AMG2850 was also tested in mice at 100 mg/kg
in a 4 h study. There was a significant decrease of Tb
from 40 min (t17 = 2.11; p < 0.05) to 140 min (t17 = 2.31;
p < 0.05) with a maximum decrease of 0.73°C at 100 min
(t17 = 2.99; p < 0.01) and plasma concentration was 54 ±
5.6 μM at 4 h post dosing (Figure 2C).
To understand whether decrease in Tb correlates







Figure 1 Characterization of five distinct compounds as TRPM8 antagonists. A) chemical structures of antagonists used in the study.
B) Concentration dependent effects of antagonists on menthol-induced intracellular calcium increase in CHO cells stably expressing rat TRPM8.
C) Concentration dependent effects of antagonists on cold (10°C)-induced intracellular calcium increase in CHO cells stably expressing rat TRPM8.
Each data point in the graph are average ± S.D. of an experiment conducted in triplicate.
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and monitored their temperatures for 24 h (Figure 2D).
In this study, AMG9678 produced a significant and
somewhat dose-dependent decrease in Tb at 10, 30
and 100 mg/kg (p.o.). The greatest decrease of Tb rela-
tive to vehicle group was 0.83°C at 1 h post dosing in
100 mg/kg administered rats, whereas 0.70°C and 0.72°C
decrease in Tb was observed at 30 and 10 mg/kg,
respectively (F3,22 = 6.46, p < 0.01) At 100 mg/kg, sig-
nificant decrease in Tb was observed from 1 to 8 h
(F3,22 = 3.99, p < 0.05). At 30 mg/kg dose, decrease in Tb
lasted for 4 h (F3,22 = 6.35, p < 0.01), whereas at 10 mg/kg,
this effect lasted for only 3 h (F3,22 = 8.56, p < 0.001). The
plasma concentrations at the end of the study (24 h
post dosing) were: 355.8 ± 116.4 nM at 100 mg/kg,
342.6 ± 97.6 nM at 30 mg/kg, and, 42.2 ± 6.4 nM at
10 mg/kg, respectively.Table 1 IC50 values of TRPM8 antagonists at different TRP cha
nanomolar except where indicated with * are shown in μM. N
Antagonist TRPM8 Menthol (Cold) TRPA1 (AITC)
AMG8788 63.2 ± 31.7 (16 ± 14) 1 ± 0.7*
AMG0635 57.2 ± 0.1 (5.5 ± 3.4) 4.5 ± 1.6*
AMG9678 31.2 ± 8.3 (6.2 ± 1.9) 0.6 ± 0.4*
Compound 496 25.8 ± 6.6 (12 ± 0.9) 5.6 ± 2.4*
AMG2850 156± 110 (7.3 ±NA) >20*The magnitude of TRPM8 blockade-induced decrease in
body temperature is reduced after repeated dosing of
an antagonist
When administered as a single dose, AMG9678-induced
decrease in Tb was transient in nature, with a peak effect
occurring within 1 h post dosing and sustained up to 12 h.
To evaluate the effect of repeated dosing on TRPM8
antagonist-induced decrease in Tb, we administered
AMG9678 once daily for 4 consecutive days to rats and
recorded Tb for 80 h (Figure 3A). AMG9678 at 30 mg/kg
produced a significant effect with maximum Tb decrease of
0.62°C at 5 h (t14 =4.27, p=0.001), 0.47°C at 26 h (t14 =4.95,
p<0.001), 0.51°C at 52 h (t14 =5.01, p<0.0001), and 0.38°C
at 75 h (t14=2.68, p<0.01), respectively, indicating a reduc-
tion of Tb decrease after repeated dosing. The decrease
in Tb lasted for 7 h after the first dosing, 5 h post second
dosing, 5 h post third dosing and 6 h post fourth dosing.nnels activated by specific agonists. Values shown are in
A=not available






Table 2 Effect of different TRPM8 antagonists on Tb in rats. P value is for comparing compound administered rat Tb
with vehicle administered rat Tb. End of the study plasma concentration is reported in μM. Asterisk indicates one-way
ANOVA followed by Dunnett's MCT
Compound Dose mg/kg (route) Max Tb decrease (°C) P value * Time post dosing (min) Plasma concentration
AMG0635 3 (p.o.) 0.47 p < 0.05 120 0.38 ± 0.04
AMG8788 30 (p.o.) 0.53 p < 0.05 40 1.5 ± 0.6
AMG9678 10 (p.o.) 0.72 p < 0.001 60 0.04 ± 0.006
AMG9678 30 (p.o.) 0.70 p < 0.01 60 0.34 ± 0.1
AMG9678 100 (p.o.) 0.83 P < 0.05 60 0.36 ± 0.12
AMG2850 100 (p.o.) 0.98 p < 0.0001 140 22 ± 0.8
Compound 496 30 (p.o.) 0.64 p < 0.01 100 14.9 ± 0.95
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7 hours post dosing) of individual animals in the drug
group relative to the average temperature of the vehicle
group is presented in Figure 3B. AMG9678-induced
0.52°C decrease in Tb relative to vehicle on the 1
st day,
and 0.30°C, 0.30°C, and 0.29°C on the 2nd, 3rd and 4th
day, respectively. One-way ANOVA followed by Tukey’s
multiple comparisons post hoc test indicates that the
decrease in Tb on day 1 is a significantly different from
each of the subsequent three days (p < 0.001) and that
the decrease in Tb on days 2–4 are not significantly dif-
ferent from each other. Even though the decrease in Tb
on day 4 is still significant compared to the vehicle, the
fact that the decrease in Tb on days 2–4 is significantly
less than that on day 1 suggests that there may be an
attenuation following repeated dosing. The plasma con-
centration at the end of study (80 h post first dosing, 7 h
post fourth dosing) was 0.41 ± 0.03 μM.
Discussion
TRPM8 channels involved in body temperature
maintenance under cold conditions
Menthol and icilin activate TRPM8 and are known to
cause an increase in Tb [32,33,38-40], however, it is not
known if TRPM8 itself is involved in Tb maintenance.
To evaluate whether TRPM8 channels are involved
in Tb maintenance, we have characterized five distinct
compounds as potent and selective antagonists of
TRPM8 and studied their effects on Tb in rats and mice.
Surprisingly, all compounds induced a small but statisti-
cally significant decrease in Tb. We believe that the
decrease in Tb is the result of TRPM8 blockade in vivo
because the antagonists used in our studies are selective
for TRPM8 compared to the other TRP channels that
we tested. Some of the antagonists used in this study
showed weak antagonism at TRPA1 (16 to 80-fold less
potent compared to TRPM8 antagonism), however,
TRPA1 antagonism in vivo with A-967079, a potent and
selective antagonist did not alter Tb [41], which suggests
that TRPM8 antagonism is responsible for decrease in
Tb in the current studies. While this manuscript was inpreparation, a structurally different TRPM8 selective
antagonist, 1-phenylethyl-4-(benzyloxy)-3-methoxybenzyl
(a-aminoethyl)carbamate also reported to cause a
decrease in Tb in wild type but not in TRPM8 knockout
mice suggesting that the decrease in Tb is exclusively
mediated by TRPM8 [42]. More recently, we reported
that another structurally different TRPM8 selective
antagonist, M8-B elicits a decrease in Tb only when
ambient temperatures reach to the activation threshold
of TRPM8 in rats (and mice) but did not affect Tb in
TRPM8 knockout mice [43]. The mechanisms of TRPM8
antagonist-induced decrease in Tb include: i) transient
delay in onset of the tail-skin vasoconstrictor response to
cold environment, ii) transient decrease in oxygen con-
sumption (metabolic heat production), and iii) transient
decrease in brown fat thermogenesis [43]. Based on the
results reported here, studies by Knowlton et al. [42],
and Almeida et al. [43], we conclude that TRPM8 is
involved in Tb maintenance under cold ambient tem-
peratures. Since all the radiotelemetry experiments
reported here are done at an ambient temperature of
20 ± 2°C, a temperature range that activates TRPM8 and
plays a role in thermoregulation, we suggest that TRPM8
appears to be not tonically active but plays a role in Tb
maintenance only in cold environment.
Members of ThermoTRP channels act as counterbalancing
thermosensors for the Tb maintenance
Antagonists of TRPV1 alone causing Tb modulation
revealed that these channels are tonically active. Since
TRPA1, TRPM8, TRPC5, TRPV3, TRPV4, and TRPV1
cover the typical environmental cold and heat sensing
range to act as thermosensors [14,18-20], activation of
these channels perhaps triggers behavioral (heat or cold
seeking behavior) as well as autonomic thermoeffectors
(vasomotor tone and thermogenesis) to maintain the Tb
at 37°C (thus constitute a basis for Tb homeostasis). It is
possible that some of the thermoTRP channels may be
tonically active (TRPV1 and other channels with activa-
tion thresholds close to Tb) whereas others may only be
active when ambient temperatures reach their activation
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Figure 2 Effects of TRPM8 antagonists on body temperature (Tb) in rats or mice. Data are presented as mean ± S.E.M. of temperature
collected for every 10 min. Statistical significance is relative to the vehicle (one tail unpaired t-test). Baseline Tb was collected for 20–30 min
before compound administration (p.o.) at time 0 and post dosing every 10 min for 120 min (A) or 240 min (B & C). The stress-induced transient
increase in Tb seen right after antagonist administration is indicated by vertical dotted lines. A) AMG8788 dosed at 30 mg/kg significantly
decreased rat Tb by 0.53°C at 40 min (t10 = 2.55; p< 0.05). B) AMG2850 dosed at 100 mg/kg significantly decreased rat Tb by 0.98°C at 140 min
(t10 = 4.38; p< 0.001). C) AMG2850 dosed at 100 mg/kg significantly decreased mouse Tb by 0.73°C at 100 min (t17 = 2.99; p< 0.001). D) TRPM8
antagonist AMG9678 induced decrease in body temperature is transient in nature. Statistical significance is relative to vehicle (one way ANOVA
followed by Dunnett’s Multiple Comparison Test). Baseline Tb was collected at 30 min before compound administration (p.o.) at time 0 and post
dosing every 1 h for 24 h. At 100 mg/kg, AMG9678 significantly decreased Tb by 0.83°C at 1 hour (F3,22 = 6.46, p < 0.01), whereas at the same time,
the maximum decrease of Tb was 0.7 and 0.72
0 C at 30 mg/kg and 10 mg/kg, respectively.
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activated channels).
Tonically active TRPV1 channels are reported to be
present in the visceral nerve terminals [35] but it is not
clear where other tonically active channels are located.
Independent of their location, tonically active ‘thermosen-
sor’ channels (TRPV1 and perhaps others) may work as
counterbalancing thermoregulators simply by their level of
activation (could be measured as maximum open prob-
ability [Po]). A change in Po of a thermosensor channel
alters Tb through recruitment of some or all thermoeffec-
tor loops and in turn altered Tb itself might trigger a
change in Po of a counterbalancing thermosensor(s), whichwill then engage some or all thermoeffector loops in the
opposite direction to bring Tb back toward 37°C. This per-
haps constitutes a fundamental basis for Tb homeostasis. It
is demonstrated clearly that modulation of thermosensors
(e.g., TRPM8 and TRPV1 by agonists and/or antagonists)
engages thermoeffectors to alter Tb [34,35,39,40], however
the demonstration of altered Tb itself changing the Po (acti-
vating) of another thermosensor awaits.
Does ThermoTRP role in Tb regulation pose a road block
to develop antagonists as therapeutics?
It is reported that TRPV1 antagonists, AMG 517, AZD
1386 and MK-2295 raised Tb in humans and all three of
Figure 3 AMG9678-induced decrease in Tb partially attenuates after repeat dosing in rats. AMG9678 was administered (p.o.) each day at
9:00 am for 4 days as indicated by an arrow. Tb data was collected every hour for 80 h and are presented as mean ± S.E.M. A) AMG9678 at
30 mg/kg produced a significant decrease of Tb by 0.62°C at 5 h (t14 = 4.27, p< 0.001), 0.47°C at 26 h (t14 = 4.95, p< 0.001), 0.51°C at 52 h
(t14 = 5.01, p< 0.0001), and 0.38°C at 75 h (t14 = 2.68, p< 0.01), respectively. The decrease in Tb lasted for 7 h post 1
st dosing, 5 h post 2nd dosing,
5 h post 3rd dosing and 6 h post 4th dosing, respectively. B. AMG9678-induced decrease in Tb reduced on day 2–4 compared to day 1. Bars
represent mean ± S.E.M. of ΔT of average 1–7 h post dosing on days 1–4.
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AMG 517 is dropped out of clinical development due to
hyperthermia [44], MK-2295 due to rightward shift in
heat tolerance (risk of accidental heat injuries), and AZD
1386 for lack of efficacy in Phase II trials [36].
Since TRPM8 antagonists elicit only a small and tran-
sient decrease in Tb, and only under ambient tempera-
tures that activate TRPM8 channels in the skin nerve
terminals ([43], this study), the decrease in Tb appears to
show attenuation after repeated dosing of an antagonist
(this study), and it is known that many pharmaceutical
and neutraceutical compounds cause a 1–2°C decreasein Tb [45], effects on thermoregulation might not pose
an issue to develop TRPM8 antagonists as therapeutics.
Concluding remarks
We propose that thermoTRP channels play both physio-
logical (thermoregulation by acting as thermosensors)
and pathophysiological (hyperalgesia) roles. Among the
ones involved in thermoregulation, some (e.g., TRPV1)
mediate thermoeffectors exclusively [35] whereas others
(e.g., TRPM8 [43] and other thermoTRPs) engage both
behavioral [40,43] as well as autonomic thermoeffectors
[43]. It is known that TRPC5 is activated by cold [46]
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temperature [15,47], but it is not known if blockade
of these channels modulates Tb. However, based on
the fact that TRPM8 and TRPV1 antagonists affect Tb,
it is plausible that some of the other thermoTRP chan-
nels may also be involved in Tb homeostasis. Future
studies should reveal the role of additional TRP channels
in thermoregulation.
Methods
Luminescence readout assay for measuring
intracellular calcium
Stable CHO cell lines expressing TRPA1, TRPM8,
TRPV1, TRPV3, and TRPV4 were generated using
tetracycline inducible T-RExTM expression system from
Invitrogen, Inc (Carlsbad, CA). In order to enable a
luminescence readout based on intracellular increase in
calcium [48], each cell line was also co-transfected with
pcDNA3.1 plasmid containing jellyfish aequorin cDNA.
Twenty four hours before the assay, cells were seeded in
96-well plates and TRP channel expression was induced
with 0.5 μg/ml tetracycline. On the day of the assay,
culture media was removed and cells were incubated
with assay buffer (F12 containing 30 mM HEPES for
TRPA1, TRPM8, and TRPV3; F12 containing 30 mM
HEPES, 1 mM CaCl2, and 0.3% BSA for TRPV4) con-
taining 15 μM coelenterazine (P.J.K, Germany) for 2 h.
Antagonists were added for 2.5 min prior to addition of
an agonist except for cold activation of TRPM8 (1 min
prior to addition of cold buffer ≤10°C). Luminescence
was measured by a CCD camera based FLASH-
luminometer built by Amgen, Inc. The following
agonists were used to activate TRP channels: 80 μM
allyl isothiocyanate for TRPA1, 100 μM menthol for
TRPM8, 0.5 μM capsaicin for TRPV1, 200 μM 2-
Aminoethoxydiphenyl borate for TRPV3, and 1 μM 4α-
phorbol 12,13-didecanoate for TRPV4 [49]. Compound
activity was calculated using either ActivityBase or
GraphPad Prism 4.01 (GraphPad Software Inc, San
Diego, CA).
Pharmacokinetics
For T1/2 determination, intravenous dosing of each com-
pound in DMSO was performed via the jugular vein in
male Sprague Dawley rats (n = 3 animals per study).
At designated time points, blood was collected via the
femoral artery in rat. Blood was collected and processed
for plasma by centrifugation. For exposure measure-
ments in radiotelemetry experiments, at the end of Tb
recording blood was collected from the animals via car-
diac puncture and processed for plasma by centrifuga-
tion. Plasma was then transferred into a 96-well
container and stored in a freezer maintained at approxi-
mately −70°C. Plasma concentrations of each test articlewere measured using sensitive LC/MS/MS methods
optimized for each compound. Non-compartmental
pharmacokinetics analysis of plasma concentrations
was conducted using WinNonlin Enterprise v.5.1.1
(Pharsight Corporation, Mountain View, CA).
Radiotelemetry in naïve rats
Animals Male Sprague Dawley rats (Harlan Laborator-
ies, Indianapolis, IN) weighing 200–350 g (6–12 weeks
of age) and male C57BL/6 mice (Taconic, Hudson, NY)
weighing 24–38 g (10–15 weeks of age) were single-
housed and acclimated for 1-week in the animal care
facility prior to start of experiments. The temperature in
the room used for animal holding and radiotelemetry
experiments was maintained at 20 ± 2°C.
Radiotelemetry probe implantation To implant the
radiotelemetry probe (model ER-4000 PDT; Mini Mitter,
Bend, OR), rats or mice were anesthetized using iso-
flourane (IsoFlo, Abbott Laboratories, Chicago, IL) at a
concentration of 4% isoflourane at 4 L/min oxygen flow.
While animals rested in a supine position, fur of the
mediolateral abdominal area was clipped and skin was
cleaned with Betadine Solution (Purdue Frederick Com-
pany, Stamford, CT) followed by 70% alcohol in water.
A 1 cm incision was made through the skin and abdom-
inal wall, such that a sterilized probe could be inserted
into the peritoneal cavity. Once inserted, the surgical site
was closed with 5–0 monocryl suture material (Ethicon
Inc, Somerville, NJ). Animals were returned to a clean
home-cage for 2 days of recovery prior to experiments.
Body temperature (Tb) measurement Overnight accli-
mation to the testing room occurred prior to the experi-
ment by placing home cages of probe-implanted, single-
housed animals on the radiotelemetry receivers. During
a less than 24 h experiment, Tb was recorded every
10 min starting with baseline Tb (prior to drug adminis-
tration) for up to 30 min and then post dosing for 2–
4 h. For a 24 h or longer study, Tb was recorded every
hour for 2 h (baseline) and then post dosing up to 80 h.
Animals (5–10 per group) were administered either
vehicle (5% Tween-80/Ora-plus) or a single to multiple
doses (dose–response study) of TRPM8 antagonists,
or once daily dosing of an antagonist for 4 days, in a
dose volume of 5 ml/kg (in vehicle, oral gavage). Blood
samples were collected at the end of the Tb recording for
pharmacokinetic analysis.
Statistical analysis All Tb data are presented as mean ±
S.E.M. In the single dose study, statistical significance of
drug treated groups was determined by comparison to
the vehicle treated group using multiple, independent
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administration (Table 2; Figure 2A-C). In the dose–
response study, all Tb data were compared to the vehicle
control group using multiple, independent one-way
analysis of variance (ANOVA) tests followed by Dunnett’s
multiple comparisons post-hoc test for significance at
each time point (AMG9678 data in Table 2; Figure 2D).
In order to assess whether the effect on temperature may
change following repeated dosing, a one-way ANOVA fol-
lowed by Tukey’s multiple comparisons post hoc test was
conducted to compare this change in temperature relative
to vehicle for each of the 4 days (Figure 3B).
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